We retrospectively analyzed melanoma tumors for LKB1 and MMP-2 using immunohistochemistry from 90 melanoma patients, including 27 BRAF V600E patients and 63 BRAF wild type patients, and correlated LKB1 expression with tumor clinicopathological parameters. This evidence concerns the gene BRAF and neoplasm.